查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1677291

性行为感染诊断市场按疾病类型、检测类型、样本类型、最终用户和分销管道划分 - 2025 年至 2030 年全球预测

Sexually Transmitted Diseases Diagnostics Market by Disease Type, Test Types, Sample Type, End-User, Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

性行为感染诊断市场预计到 2024 年将达到 127.8 亿美元，到 2025 年将达到 135.3 亿美元，到 2030 年将达到 181.7 亿美元，复合年增长率为 6.03%。

主要市场统计数据
基准年 2024 年 127.8亿美元
预计 2025 年 135.3亿美元
预测年份 2030 181.7亿美元
复合年增长率（%） 6.03%

在性行为感染传染病 (STD) 诊断这一动态领域，不断的技术创新和不断发展的医疗实践正在重塑疾病的检测和管理方式。随着全球性传染病负担不断增加，对快速、准确且易于取得的诊断解决方案的需求从未如此强烈。现代诊断技术不仅提高了准确性，而且大大减少了检测时间，为早期治疗和预防铺平了道路。这份全面的摘要详细概述了影响市场的关键驱动因素，提供了对细分和区域表现的见解，并强调了在该关键领域运营的公司的战略方向。

当前阶段的技术进步和综合诊断程序正在改变传统的医疗实践。从实验室专业人员和临床医生到公共卫生策略家，相关人员都受益于精准和快速反应的时代。正如我们将在以下章节中讨论的那样，诊断领域正在经历重大变革时期，这将影响市场动态和患者照护。本报告透过最新资料和趋势阐明了这些转变，这对于试图驾驭临床需求和技术创新之间复杂相互作用的决策者至关重要。

改变性行为感染诊断市场

近年来，变革性的技术、监管和市场变化重新定义了性传染感染诊断产业。分子生物学和数位分析的进步促进了照护现场和实验室检测方法的快速改进。这些创新提高了诊断的准确性，缩短了检测时间，并使不同患者群体更容易接受检测。同时，法律规范和报销政策的变化为市场参与企业创造了新的机会，同时迫使现有企业重新调整产品系列。

核酸扩增技术和快速血浆再评估检测等新技术现已成为下一代诊断技术的支柱。这些技术，加上与用于资料解释和远端监控的数位系统的日益集成，使临床医生能够做出更明智的决策。这种演变不仅限于临床应用，还延伸到了市场动态，转向针对患者概况和本地医疗保健基础设施量身定制的个人化诊断解决方案。随着竞争格局适应这些新趋势，相关人员被鼓励不断创新，确保服务交付的速度与诊断能力的快速进步相符。

深入了解性传染感染诊断的关键环节

市场区隔的详细分析可以让我们清楚了解 STI 诊断生态系统的各个方面。它根据疾病类型对市场进行剖析，检查主要病原体，包括披衣菌感染、淋病、单纯疱疹病毒 (HSV)、人类免疫力缺乏病毒 (HIV)、人类乳突病毒 (HPV) 和梅毒。这种详细的分类揭示了集体爆发发生率、人口影响和地理流行的清晰模式。关于测试类型的调查主要集中于实验室测试与就地检验。实验室检测已被广泛研究，包括酵素结合免疫吸附检测法(ELISA)、核酸增幅检查(NAAT) 和快速血浆反应检测 (RPR) 等成熟技术，而就地检验包括家庭检测套组和快速检测等工具。基于样本类型的研究检查了血液、尿液和阴道拭子的诊断效用，强调了与每种样本相关的不同敏感性和特异性。细分继续透过分析最终用户概况来进行，范围包括居家医疗、医院/诊所、护理点、公共卫生实验室和研究实验室。最后，我们进一步按分销管道细分市场，比较直销与代理商网络，以确定市场渗透率和服务交付效率。这种细緻的细分研究突显了每个细分市场独特的复杂性和不同需求，从而影响诊断策略和投资。

目录

第 1 章 简介

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

  • 市场动态
    • 驱动程式
      • 全球性行为感染传染病的发生率和认知度不断上升
      • 政府和卫生组织加强支持政策和措施的实施力度
      • 它将扩大医疗保健服务的覆盖率，并提高全球性行为感染诊断服务的可用性和利用率。
    • 限制因素
      • 与诊断检测是否能够跟上不断演化的菌株和新病原体有关的问题
    • 机会
      • 透过诊断公司和医疗保健提供者或非政府组织之间的合作实现成长的潜力
      • 创新就地检验，减少对专业实验室和医护人员的需求
    • 任务
      • 与跨多个地区的复杂法规环境相关的担忧
  • 市场区隔分析
    • 疾病类型：披衣菌感染核酸增幅检查具有高度敏感性和特异性，因此越来越有必要。
    • 最终用户：医院和诊所性行为感染诊断的应用将迅速增加，从而实现准确、及时的诊断。
  • 波特五力分析
  • PESTEL 分析
    • 政治的
    • 经济
    • 社会的
    • 技术的
    • 合法的
    • 环境

第六章性行为感染传染病诊断市场（依疾病类型）

  • 披衣菌感染
  • 淋病
  • 单纯疱疹病毒 (HSV)
  • 人类免疫力缺乏病毒（HIV）
  • 人类乳突病毒 (HPV)
  • 梅毒

第 7 章性行为感染传染病诊断市场（按测试类型）

  • 实验室测试
    • 酵素免疫分析法（ELISA）
    • 核酸增幅检查（NAAT）
    • 快速血浆反应素 (RPR)
  • 就地检验
    • 家庭检测套组
    • 快速检测

第 8 章性行为感染传染病诊断市场（依样本类型）

  • 血
  • 尿
  • 阴道拭子

第 9 章性行为感染传染病诊断市场（依最终用户）

  • 家庭护理设置
  • 医院和诊所
  • 照护现场设置
  • 公共卫生研究所
  • 研究部门

第 10 章性行为感染传染病诊断市场（依通路）

  • 直接销售
  • 经销商

11.美洲性行为感染传染病诊断市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

12. 亚太地区性行为感染传染病诊断市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

13. 欧洲、中东和非洲性行为感染传染病诊断市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十四章 竞争格局

  • 2024 年市场占有率分析
  • FPNV 定位矩阵，2024 年
  • 竞争情境分析
  • 战略分析与建议

公司列表

  • Abbott Laboratories
  • Astra Biotech GmbH
  • Becton Dickinson and company
  • Bio-Rad Laboratories, Inc.
  • bioMerieux SA
  • Danaher Corporation
  • Daye Limited
  • Diasorin SpA
  • F. Hoffmann-La Roche Ltd.
  • Geneproof
  • Hologic Inc.
  • Jiangsu BioPerfectus Technologies Co., Ltd
  • Liferiver Bio-Tech Corp.
  • MedMira Inc.
  • Merck KGaA
  • Meridian Bioscience Inc.
  • Mylab Discovery Solutions Pvt. Ltd.
  • Novartis AG
  • OraSure Technologies, Inc.
  • Qiagen Inc.
  • Quest Consumer Inc.
  • Sansure Biotech Inc.
  • Seegene Inc.
  • Siemens Healthineers AG
  • Thermo Fisher Scientific, Inc.
Product Code: MRR-5319A8C1C5A6

The Sexually Transmitted Diseases Diagnostics Market was valued at USD 12.78 billion in 2024 and is projected to grow to USD 13.53 billion in 2025, with a CAGR of 6.03%, reaching USD 18.17 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 12.78 billion
Estimated Year [2025] USD 13.53 billion
Forecast Year [2030] USD 18.17 billion
CAGR (%) 6.03%

In the dynamic field of sexually transmitted diseases (STDs) diagnostics, constant innovation and evolving healthcare practices are reshaping how diseases are detected and managed. As the global burden of STDs continues to rise, the need for prompt, accurate, and accessible diagnostic solutions has never been more critical. Modern diagnostic technologies are not only improving accuracy but are also drastically reducing turnaround times, paving the way for early treatment and prevention. This comprehensive summary provides an in-depth overview of the key drivers influencing the market, offers insights into segmentation and regional performance, and highlights strategic directions for companies engaged in this critical space.

The current stage of integration between technological advancements and diagnostic procedures is transforming traditional practices. Stakeholders, ranging from laboratory professionals and clinicians to public health strategists, are benefiting from an era marked by precision and rapid response. As we explore in subsequent sections, the diagnostic landscape is undergoing significant transformative shifts that influence market dynamics and patient care. This report sheds light on these shifts, drawing on recent data and trends essential for decision-makers looking to navigate the complex interplay between clinical needs and technological innovations.

Transformative Shifts in the STI Diagnostics Industry Landscape

Over recent years, transformative shifts across technological, regulatory, and market dimensions have redefined the STI diagnostics industry. Advances in molecular biology and digital analytics have led to rapid enhancements in point-of-care and laboratory testing modalities. These innovations have bolstered diagnostic accuracy, reduced testing timeframes, and made testing more accessible to diverse patient populations. In parallel, changes in regulatory frameworks and reimbursement policies have opened up new opportunities for market entrants, while prompting established companies to recalibrate their product portfolios.

Emerging technologies such as nucleic acid amplification techniques and rapid plasma reevaluation assays now serve as the backbone for next-generation diagnostics. These technologies, coupled with the increasing integration of digital systems for data interpretation and remote monitoring, are enabling clinicians to make more informed decisions. This evolution is not limited to clinical application alone; it extends to market dynamics as well, with an observable shift towards personalized diagnostic solutions that are tailored to both patient demographics and regional healthcare infrastructures. As competitive landscapes adjust to these emerging trends, stakeholders are urged to innovate continuously, ensuring that the pace of service delivery matches the rapid advances in diagnostic capabilities.

Key Segmentation Insights in STI Diagnostics

A detailed analysis of market segmentation provides a clear understanding of the diverse dimensions characterizing the STI diagnostics ecosystem. The market is dissected based on disease type, examining key pathogens including Chlamydia, Gonorrhea, Herpes Simplex Virus (HSV), Human Immunodeficiency Virus (HIV), Human Papillomavirus (HPV), and Syphilis. This detailed categorization reveals distinct patterns in outbreak incidences, demographic impacts, and regional prevalence. In our investigation of test types, the focus is on the contrast between laboratory testing and point-of-care testing. Laboratory testing is extensively researched through established techniques such as Enzyme-linked Immunosorbent Assays (ELISA), Nucleic Acid Amplification Tests (NAATs), and Rapid Plasma Reagin (RPR), while point-of-care testing encompasses tools including home testing kits and rapid tests. An exploration based on sample type looks into the diagnostic utility of blood, urine, and vaginal swabs, highlighting different sensitivities and specificities pertinent to each sample. The segmentation continues with an analysis on end-user profiles, ranging from homecare settings, hospitals and clinics, and point-of-care settings to public health labs and research laboratories. Finally, the market is further segmented by distribution channel, comparing direct sales with distributor networks to elucidate market penetration and service delivery efficiencies. These nuanced segmentation studies underline the complexity and tailored needs inherent to each market segment, influencing diagnostic strategies and investments.

Based on Disease Type, market is studied across Chlamydia, Gonorrhea, Herpes Simplex Virus (HSV), Human Immunodeficiency Virus (HIV), Human Papillomavirus (HPV), and Syphilis.

Based on Test Types, market is studied across Laboratory Testing and Point-of-Care Testing. The Laboratory Testing is further studied across Enzyme-linked Immunosorbent Assay (ELISA), Nucleic Acid Amplification Tests (NAATs), and Rapid Plasma Reagin (RPR). The Point-of-Care Testing is further studied across Home Testing Kits and Rapid Tests.

Based on Sample Type, market is studied across Blood, Urine, and Vaginal Swabs.

Based on End-User, market is studied across Homecare Settings, Hospitals & Clinics, Point-of-Care Settings, Public Health Labs, and Research Laboratories.

Based on Distribution Channel, market is studied across Direct Sales and Distributors.

Regional Dynamics Shaping the STI Diagnostics Market

The global STI diagnostics market exhibits varied growth trajectories influenced by regional healthcare frameworks and economic priorities. The Americas are witnessing rapid adoption of advanced diagnostic tools driven by an increasing emphasis on early detection and preventive care. In addition, regulatory support and robust healthcare infrastructure are accelerating the integration of innovative testing methodologies, making the region one of the most dynamic in the current landscape. Europe, the Middle East, and Africa collectively present a diverse set of challenges and opportunities. European markets lead in regulatory compliance and technological advancements, while the Middle East and Africa provide emerging markets with significant unmet diagnostic needs. Each of these regions is responding to local challenges by adopting scalable diagnostic solutions that resonate with public health strategies. The Asia-Pacific region, characterized by rapid economic growth and a burgeoning population, is increasingly focusing on the implementation of cost-effective and accessible diagnostic platforms. Region-specific trends, workforce capabilities, and healthcare investments are all influencing the manner in which diagnostics evolve to meet distinct regional requirements. Together, these regional insights offer a comprehensive view of the disparate yet interconnected elements that drive market innovation and expansion on a worldwide scale.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Leading Companies and Their Impact on Diagnostic Innovations

The STI diagnostics market landscape is highly competitive, with several prominent companies driving technological advancements and market growth. Industry leaders such as Abbott Laboratories, Astra Biotech GmbH, Becton Dickinson and company, Bio-Rad Laboratories, Inc., and bioMerieux SA are at the forefront of innovation, developing robust tools and platforms that redefine diagnostic accuracy. In addition, powerhouses like Danaher Corporation, Daye Limited, Diasorin S.p.A, F. Hoffmann-La Roche Ltd., and Geneproof continue to build upon rich legacies in diagnostic research and clinical application. The influence of companies such as Hologic Inc., Jiangsu BioPerfectus Technologies Co., Ltd, Liferiver Bio-Tech Corp., and MedMira Inc. is reflected in their rapid adoption of state-of-the-art diagnostic technologies, contributing to enhanced patient outcomes across multiple regions. Furthermore, distinguished names like Merck KGaA, Meridian Bioscience Inc., Mylab Discovery Solutions Pvt. Ltd., Novartis AG, OraSure Technologies, Inc., Qiagen Inc., Quest Consumer Inc., Sansure Biotech Inc., Seegene Inc., Siemens Healthineers AG, and Thermo Fisher Scientific, Inc. are emblematic of the drive toward innovation and comprehensive disease management. These companies are continuously pushing the boundaries of diagnostic science, with ongoing investments in research and development fostering an ecosystem that supports both rapid technological innovations and strategic collaborations across the healthcare network.

The report delves into recent significant developments in the Sexually Transmitted Diseases Diagnostics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Astra Biotech GmbH, Becton Dickinson and company, Bio-Rad Laboratories, Inc., bioMerieux SA, Danaher Corporation, Daye Limited, Diasorin S.p.A, F. Hoffmann-La Roche Ltd., Geneproof, Hologic Inc., Jiangsu BioPerfectus Technologies Co., Ltd, Liferiver Bio-Tech Corp., MedMira Inc., Merck KGaA, Meridian Bioscience Inc., Mylab Discovery Solutions Pvt. Ltd., Novartis AG, OraSure Technologies, Inc., Qiagen Inc., Quest Consumer Inc., Sansure Biotech Inc., Seegene Inc., Siemens Healthineers AG, and Thermo Fisher Scientific, Inc.. Strategic Recommendations for Industry Leaders in STI Diagnostics

In light of the critical shifts and segmentation complexities inherent in the STI diagnostics market, industry leaders are encouraged to adopt a series of actionable strategies. Foremost, it is imperative that companies invest in the advancement of both molecular diagnostic technologies and digital analytic platforms that not only enhance operational efficiency but also ensure timely and precise results. This involves a reallocation of resources towards research and development, with a focus on emerging technologies that have demonstrated potential in enhancing sensitivity and specificity. In parallel, firms should consider strategic collaborations with regulatory bodies and academic institutions to streamline the translation of innovative diagnostic technologies into market-ready solutions. Capitalizing on regional strengths and diversifying distribution strategies is essential, particularly by leveraging the heterogeneous needs of diverse customer segments identified through the segmentation studies. Enhancing communication channels with end-user groups such as hospitals, public health labs, and homecare settings will further ensure that the developed diagnostic tools meet practical clinical needs. Additionally, a measured expansion into emerging markets, supported by localized product adaptations and pricing strategies, will drive sustainable growth. A cohesive strategy merging technological innovation with effective market penetration and strategic partnerships is likely to secure a competitive edge in this rapidly evolving field.

Synthesis and Conclusive Insights on STI Diagnostics

In summary, the landscape of sexually transmitted diseases diagnostics is undergoing transformative changes powered by technological breakthroughs, evolving regulatory frameworks, and an increased emphasis on precision medicine. The analysis provided in this report uncovers multifaceted segmentation across disease types, test modalities, sample types, end-user classifications, and distribution channels - all of which contribute to a comprehensive understanding of market dynamics and strategic opportunities. Regional insights highlight significant discrepancies in market maturity and adoption rates, while leading companies continuously push the envelope in both innovation and application. The integration of state-of-the-art diagnostic techniques with effective market strategies is paving the way for improved patient outcomes and enhanced public health responses. This synthesis bridges the gap between clinical innovation and market trends, urging stakeholders to focus on sustained investment in evolving technologies and strategic partnerships. Thus, the confluence of these factors not only solidifies the current market status but also paves the way for future advancements in the detection and management of sexually transmitted diseases.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising incidence and awareness of STDs globally
      • 5.1.1.2. Growing implementation of supportive policies and initiatives from governments and health organizations
      • 5.1.1.3. Expanded access to healthcare services facilitates greater availability and use of STD diagnostic services across globe
    • 5.1.2. Restraints
      • 5.1.2.1. Issues related to ability to keep diagnostic tests up-to-date with evolving strains and emerging pathogens
    • 5.1.3. Opportunities
      • 5.1.3.1. Growing potential with partnerships between diagnostic companies and healthcare providers or NGOs
      • 5.1.3.2. Innovations in point-of-care testing to reduce the need for specialized laboratories and healthcare personnel
    • 5.1.4. Challenges
      • 5.1.4.1. Concerns associated with complex regulatory environments across different regions
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Disease Type: Increasing need for nucleic acid amplification tests in chlamydia owing to high sensitivity and specificity
    • 5.2.2. End-User: Proliferating applications of STD diagnostics in hospitals and clinics for accurate and timely diagnosis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Sexually Transmitted Diseases Diagnostics Market, by Disease Type

  • 6.1. Introduction
  • 6.2. Chlamydia
  • 6.3. Gonorrhea
  • 6.4. Herpes Simplex Virus (HSV)
  • 6.5. Human Immunodeficiency Virus (HIV)
  • 6.6. Human Papillomavirus (HPV)
  • 6.7. Syphilis

7. Sexually Transmitted Diseases Diagnostics Market, by Test Types

  • 7.1. Introduction
  • 7.2. Laboratory Testing
    • 7.2.1. Enzyme-linked Immunosorbent Assay (ELISA)
    • 7.2.2. Nucleic Acid Amplification Tests (NAATs)
    • 7.2.3. Rapid Plasma Reagin (RPR)
  • 7.3. Point-of-Care Testing
    • 7.3.1. Home Testing Kits
    • 7.3.2. Rapid Tests

8. Sexually Transmitted Diseases Diagnostics Market, by Sample Type

  • 8.1. Introduction
  • 8.2. Blood
  • 8.3. Urine
  • 8.4. Vaginal Swabs

9. Sexually Transmitted Diseases Diagnostics Market, by End-User

  • 9.1. Introduction
  • 9.2. Homecare Settings
  • 9.3. Hospitals & Clinics
  • 9.4. Point-of-Care Settings
  • 9.5. Public Health Labs
  • 9.6. Research Laboratories

10. Sexually Transmitted Diseases Diagnostics Market, by Distribution Channel

  • 10.1. Introduction
  • 10.2. Direct Sales
  • 10.3. Distributors

11. Americas Sexually Transmitted Diseases Diagnostics Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Sexually Transmitted Diseases Diagnostics Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Sexually Transmitted Diseases Diagnostics Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2024
  • 14.2. FPNV Positioning Matrix, 2024
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. Labcorp and NOWDiagnostics collaborate to expand rapid syphilis testing amid rising STI cases nationwide
    • 14.3.2. Sherlock Biosciences innovative clinical trial for rapid OTC STI diagnostics
    • 14.3.3. Binx Health secures USD 65 million to enhance rapid point-of-care STI diagnostics
  • 14.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Astra Biotech GmbH
  • 3. Becton Dickinson and company
  • 4. Bio-Rad Laboratories, Inc.
  • 5. bioMerieux SA
  • 6. Danaher Corporation
  • 7. Daye Limited
  • 8. Diasorin S.p.A
  • 9. F. Hoffmann-La Roche Ltd.
  • 10. Geneproof
  • 11. Hologic Inc.
  • 12. Jiangsu BioPerfectus Technologies Co., Ltd
  • 13. Liferiver Bio-Tech Corp.
  • 14. MedMira Inc.
  • 15. Merck KGaA
  • 16. Meridian Bioscience Inc.
  • 17. Mylab Discovery Solutions Pvt. Ltd.
  • 18. Novartis AG
  • 19. OraSure Technologies, Inc.
  • 20. Qiagen Inc.
  • 21. Quest Consumer Inc.
  • 22. Sansure Biotech Inc.
  • 23. Seegene Inc.
  • 24. Siemens Healthineers AG
  • 25. Thermo Fisher Scientific, Inc.

LIST OF FIGURES

  • FIGURE 1. SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET MULTI-CURRENCY
  • FIGURE 2. SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET MULTI-LANGUAGE
  • FIGURE 3. SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET RESEARCH PROCESS
  • FIGURE 4. SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, 2024 VS 2030
  • FIGURE 5. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 6. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2024 VS 2030 (%)
  • FIGURE 9. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2024 VS 2030 (%)
  • FIGURE 11. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2030 (%)
  • FIGURE 13. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
  • FIGURE 15. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 16. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
  • FIGURE 17. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 18. AMERICAS SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 19. AMERICAS SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 20. UNITED STATES SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 21. UNITED STATES SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 23. ASIA-PACIFIC SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 24. EUROPE, MIDDLE EAST & AFRICA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 25. EUROPE, MIDDLE EAST & AFRICA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 26. SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 27. SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY CHLAMYDIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY GONORRHEA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY HERPES SIMPLEX VIRUS (HSV), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY HUMAN IMMUNODEFICIENCY VIRUS (HIV), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY HUMAN PAPILLOMAVIRUS (HPV), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SYPHILIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS (NAATS), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY RAPID PLASMA REAGIN (RPR), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY HOME TESTING KITS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY RAPID TESTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY BLOOD, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY URINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY VAGINAL SWABS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY PUBLIC HEALTH LABS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DIRECT SALES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. AMERICAS SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. AMERICAS SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
  • TABLE 39. AMERICAS SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 40. AMERICAS SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
  • TABLE 41. AMERICAS SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. AMERICAS SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 43. AMERICAS SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 44. AMERICAS SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 45. ARGENTINA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. ARGENTINA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
  • TABLE 47. ARGENTINA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 48. ARGENTINA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
  • TABLE 49. ARGENTINA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. ARGENTINA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 51. ARGENTINA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 52. BRAZIL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. BRAZIL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
  • TABLE 54. BRAZIL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 55. BRAZIL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
  • TABLE 56. BRAZIL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. BRAZIL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 58. BRAZIL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 59. CANADA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. CANADA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
  • TABLE 61. CANADA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 62. CANADA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
  • TABLE 63. CANADA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. CANADA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 65. CANADA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 66. MEXICO SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. MEXICO SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
  • TABLE 68. MEXICO SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 69. MEXICO SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
  • TABLE 70. MEXICO SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. MEXICO SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 72. MEXICO SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 73. UNITED STATES SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. UNITED STATES SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
  • TABLE 75. UNITED STATES SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 76. UNITED STATES SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
  • TABLE 77. UNITED STATES SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. UNITED STATES SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 79. UNITED STATES SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 80. UNITED STATES SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 81. ASIA-PACIFIC SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. ASIA-PACIFIC SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
  • TABLE 83. ASIA-PACIFIC SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 84. ASIA-PACIFIC SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
  • TABLE 85. ASIA-PACIFIC SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. ASIA-PACIFIC SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 87. ASIA-PACIFIC SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 88. ASIA-PACIFIC SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 89. AUSTRALIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. AUSTRALIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
  • TABLE 91. AUSTRALIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 92. AUSTRALIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
  • TABLE 93. AUSTRALIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. AUSTRALIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 95. AUSTRALIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 96. CHINA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. CHINA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
  • TABLE 98. CHINA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 99. CHINA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
  • TABLE 100. CHINA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. CHINA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 102. CHINA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 103. INDIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. INDIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
  • TABLE 105. INDIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 106. INDIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
  • TABLE 107. INDIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. INDIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 109. INDIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 110. INDONESIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. INDONESIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
  • TABLE 112. INDONESIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 113. INDONESIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
  • TABLE 114. INDONESIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. INDONESIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 116. INDONESIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 117. JAPAN SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. JAPAN SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
  • TABLE 119. JAPAN SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 120. JAPAN SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
  • TABLE 121. JAPAN SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. JAPAN SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 123. JAPAN SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 124. MALAYSIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. MALAYSIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
  • TABLE 126. MALAYSIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 127. MALAYSIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
  • TABLE 128. MALAYSIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. MALAYSIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 130. MALAYSIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 131. PHILIPPINES SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. PHILIPPINES SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
  • TABLE 133. PHILIPPINES SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 134. PHILIPPINES SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
  • TABLE 135. PHILIPPINES SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. PHILIPPINES SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 137. PHILIPPINES SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 138. SINGAPORE SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. SINGAPORE SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
  • TABLE 140. SINGAPORE SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 141. SINGAPORE SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
  • TABLE 142. SINGAPORE SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. SINGAPORE SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 144. SINGAPORE SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 145. SOUTH KOREA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. SOUTH KOREA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
  • TABLE 147. SOUTH KOREA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 148. SOUTH KOREA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
  • TABLE 149. SOUTH KOREA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 150. SOUTH KOREA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 151. SOUTH KOREA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 152. TAIWAN SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 153. TAIWAN SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
  • TABLE 154. TAIWAN SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 155. TAIWAN SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
  • TABLE 156. TAIWAN SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 157. TAIWAN SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 158. TAIWAN SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 159. THAILAND SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 160. THAILAND SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
  • TABLE 161. THAILAND SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 162. THAILAND SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
  • TABLE 163. THAILAND SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 164. THAILAND SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 165. THAILAND SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 166. VIETNAM SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 167. VIETNAM SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
  • TABLE 168. VIETNAM SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 169. VIETNAM SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
  • TABLE 170. VIETNAM SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. VIETNAM SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 172. VIETNAM SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 173. EUROPE, MIDDLE EAST & AFRICA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 174. EUROPE, MIDDLE EAST & AFRICA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
  • TABLE 175. EUROPE, MIDDLE EAST & AFRICA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 176. EUROPE, MIDDLE EAST & AFRICA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
  • TABLE 177. EUROPE, MIDDLE EAST & AFRICA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 178. EUROPE, MIDDLE EAST & AFRICA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 179. EUROPE, MIDDLE EAST & AFRICA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 180. EUROPE, MIDDLE EAST & AFRICA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 181. DENMARK SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 182. DENMARK SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
  • TABLE 183. DENMARK SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 184. DENMARK SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
  • TABLE 185. DENMARK SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 186. DENMARK SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 187. DENMARK SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 188. EGYPT SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 189. EGYPT SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
  • TABLE 190. EGYPT SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 191. EGYPT SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
  • TABLE 192. EGYPT SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 193. EGYPT SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 194. EGYPT SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 195. FINLAND SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 196. FINLAND SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
  • TABLE 197. FINLAND SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 198. FINLAND SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
  • TABLE 199. FINLAND SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 200. FINLAND SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 201. FINLAND SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 202. FRANCE SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 203. FRANCE SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
  • TABLE 204. FRANCE SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 205. FRANCE SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
  • TABLE 206. FRANCE SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 207. FRANCE SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 208. FRANCE SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 209. GERMANY SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 210. GERMANY SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
  • TABLE 211. GERMANY SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 212. GERMANY SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
  • TABLE 213. GERMANY SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 214. GERMANY SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 215. GERMANY SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 216. ISRAEL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 217. ISRAEL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
  • TABLE 218. ISRAEL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 219. ISRAEL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
  • TABLE 220. ISRAEL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 221. ISRAEL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 222. ISRAEL SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 223. ITALY SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 224. ITALY SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
  • TABLE 225. ITALY SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 226. ITALY SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
  • TABLE 227. ITALY SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 228. ITALY SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 229. ITALY SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 230. NETHERLANDS SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 231. NETHERLANDS SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
  • TABLE 232. NETHERLANDS SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 233. NETHERLANDS SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
  • TABLE 234. NETHERLANDS SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 235. NETHERLANDS SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 236. NETHERLANDS SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 237. NIGERIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 238. NIGERIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
  • TABLE 239. NIGERIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 240. NIGERIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
  • TABLE 241. NIGERIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 242. NIGERIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 243. NIGERIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 244. NORWAY SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 245. NORWAY SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
  • TABLE 246. NORWAY SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 247. NORWAY SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
  • TABLE 248. NORWAY SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 249. NORWAY SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 250. NORWAY SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 251. POLAND SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 252. POLAND SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
  • TABLE 253. POLAND SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 254. POLAND SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
  • TABLE 255. POLAND SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 256. POLAND SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 257. POLAND SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 258. QATAR SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 259. QATAR SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
  • TABLE 260. QATAR SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 261. QATAR SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
  • TABLE 262. QATAR SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 263. QATAR SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 264. QATAR SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 265. RUSSIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 266. RUSSIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
  • TABLE 267. RUSSIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 268. RUSSIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
  • TABLE 269. RUSSIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 270. RUSSIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 271. RUSSIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 272. SAUDI ARABIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 273. SAUDI ARABIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY TEST TYPES, 2018-2030 (USD MILLION)
  • TABLE 274. SAUDI ARABIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY LABORATORY TESTING, 2018-2030 (USD MILLION)
  • TABLE 275. SAUDI ARABIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY POINT-OF-CARE TESTING, 2018-2030 (USD MILLION)
  • TABLE 276. SAUDI ARABIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
  • TABLE 277. SAUDI ARABIA SEXUALLY TRANSMITTED DISEASES DIAGNOSTICS MARKET SIZE, BY END-USER, 2